{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T22:11:20Z","timestamp":1768601480592,"version":"3.49.0"},"posted":{"date-parts":[[2023,1,18]]},"group-title":"Dermatology","reference-count":35,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,1,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cutaneous immune-related adverse events (cirAEs) occur in up to 40% of immune checkpoint inhibitor (ICI) recipients. However, the association of cirAEs with survival remains unclear.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the association of cirAEs with survival among ICI recipients.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>ICI recipients were identified from the Mass General Brigham healthcare system (MGB) and Dana-Farber Cancer Institute (DFCI). Patient charts were reviewed for cirAE development within 2 years after ICI initiation. Multivariate time-varying Cox proportional hazards models, adjusted for age, sex, race\/ethnicity, Charlson Comorbidity Index, ICI type, cancer type, and year of ICI initiation were utilized to investigate the impact of cirAE development on overall survival.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 3,731 ICI recipients, 18.1% developed a cirAE. 6-month landmark analysis and time-varying Cox proportional hazards models demonstrated that patients who developed cirAEs were associated with decreased mortality (HR=0.87,p=0.027), particularly in melanoma patients (HR=0.67,p=0.003). Among individual morphologies, lichenoid eruption (HR=0.51,p&lt;0.001), psoriasiform eruption (HR=0.52,p=0.005), vitiligo (HR=0.29,p=0.007), isolated pruritus without visible manifestation of rash (HR=0.71,p=0.007), acneiform eruption (HR =0.34,p=0.025), and non-specific rash (HR=0.68, p&lt;0.001) were significantly associated with better survival after multiple comparisons adjustment.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Limitations<\/jats:title>\n                  <jats:p>Retrospective design; single geography.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>CirAE development is associated with improved survival among ICI recipients, especially melanoma patients.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Capsule Summary<\/jats:title>\n                  <jats:list list-type=\"bullet\">\n                    <jats:list-item>\n                      <jats:p>Patients on immune checkpoint inhibitors (ICIs) who developed cutaneous immune-related adverse events (cirAEs) had favorable outcomes. This was especially notable for melanoma patients who had cirAEs, both those with vitiligo and other morphologies.<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>Development of cirAEs in ICI-treated patients can be used to prognosticate survival and guide treatment decisions.<\/jats:p>\n                    <\/jats:list-item>\n                  <\/jats:list>\n                <\/jats:sec>","DOI":"10.1101\/2023.01.16.23284635","type":"posted-content","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T12:45:16Z","timestamp":1674045916000},"source":"Crossref","is-referenced-by-count":0,"title":["Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study"],"prefix":"10.64898","author":[{"given":"Shijia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guihong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nga","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pearl","family":"Ugwu-Dike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neel","family":"Raval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayhyun","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora A.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruple","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Phillipps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonnie W.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Roster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyre","family":"Zubiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve","family":"Boland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hensin","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadmehr","family":"Demehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9892-8218","authenticated-orcid":false,"given":"Kun-Hsing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Gusev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yevgeniy R.","family":"Semenov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"issue":"8","key":"2023012010053126000_2023.01.16.23284635v1.1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","year":"2020","journal-title":"Cell research"},{"key":"2023012010053126000_2023.01.16.23284635v1.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190084"},{"issue":"3","key":"2023012010053126000_2023.01.16.23284635v1.3","doi-asserted-by":"crossref","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","year":"2020","journal-title":"JAMA network open"},{"issue":"17","key":"2023012010053126000_2023.01.16.23284635v1.4","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","year":"2018","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"5","key":"2023012010053126000_2023.01.16.23284635v1.5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamadermatol.2021.0326","article-title":"Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced cancer","volume":"157","year":"2021","journal-title":"JAMA dermatology"},{"key":"2023012010053126000_2023.01.16.23284635v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.11.050"},{"key":"2023012010053126000_2023.01.16.23284635v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.054"},{"key":"2023012010053126000_2023.01.16.23284635v1.8","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5476"},{"key":"2023012010053126000_2023.01.16.23284635v1.9","unstructured":"Nalichowski R , Keogh D , Chueh HC , Murphy SN . Calculating the benefits of a Research Patient Data Repository. AMIA. Annual Symposium proceedings AMIA Symposium. Published online 20068."},{"key":"2023012010053126000_2023.01.16.23284635v1.10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-4-94"},{"key":"2023012010053126000_2023.01.16.23284635v1.11","unstructured":"\u201cCommon Terminology Criteria for Adverse Events (CTCAE).\u201d Cancer Therapy Evaluation Program (CTEP), National Cancer Institute, 21 Sept. 2020, https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"2023012010053126000_2023.01.16.23284635v1.12","doi-asserted-by":"crossref","unstructured":"L\u00e9vesque LE , Hanley JA , Kezouh A , Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. Bmj. 2010;340.","DOI":"10.1136\/bmj.b5087"},{"key":"2023012010053126000_2023.01.16.23284635v1.13","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13081"},{"key":"2023012010053126000_2023.01.16.23284635v1.14","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.02.12"},{"key":"2023012010053126000_2023.01.16.23284635v1.15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12874-017-0405-6","article-title":"Statistical methods for elimination of guarantee-time bias in cohort studies: a simulation study","volume":"17","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"2023012010053126000_2023.01.16.23284635v1.16","doi-asserted-by":"crossref","unstructured":"Wongvibulsin S , Pahalyants V , Kalinich M , et al. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune checkpoint inhibitors: A United States population-level analysis. J Am Acad Dermatol. Published online 2021:1-10.","DOI":"10.1016\/j.jid.2021.02.401"},{"key":"2023012010053126000_2023.01.16.23284635v1.17","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0805-8"},{"key":"2023012010053126000_2023.01.16.23284635v1.18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050989"},{"key":"2023012010053126000_2023.01.16.23284635v1.19","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000300"},{"key":"2023012010053126000_2023.01.16.23284635v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.357"},{"key":"2023012010053126000_2023.01.16.23284635v1.21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192179"},{"key":"2023012010053126000_2023.01.16.23284635v1.22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3054"},{"key":"2023012010053126000_2023.01.16.23284635v1.23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.629722"},{"key":"2023012010053126000_2023.01.16.23284635v1.24","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15345"},{"key":"2023012010053126000_2023.01.16.23284635v1.25","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13520"},{"key":"2023012010053126000_2023.01.16.23284635v1.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4756"},{"key":"2023012010053126000_2023.01.16.23284635v1.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0305"},{"key":"2023012010053126000_2023.01.16.23284635v1.28","doi-asserted-by":"publisher","DOI":"10.2217\/imt.11.62"},{"key":"2023012010053126000_2023.01.16.23284635v1.29","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8636"},{"key":"2023012010053126000_2023.01.16.23284635v1.30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00107.x"},{"key":"2023012010053126000_2023.01.16.23284635v1.31","doi-asserted-by":"publisher","DOI":"10.1038\/23495"},{"key":"2023012010053126000_2023.01.16.23284635v1.32","doi-asserted-by":"publisher","DOI":"10.1038\/40166"},{"key":"2023012010053126000_2023.01.16.23284635v1.33","doi-asserted-by":"publisher","DOI":"10.1038\/nature10851"},{"key":"2023012010053126000_2023.01.16.23284635v1.34","doi-asserted-by":"crossref","unstructured":"Chen S , LeBoeuf N , Reynolds K , Semenov Y. 1263 Dermatologic immune related adverse event disease definitions: a multi-institutional Delphi consensus project presented on behalf of the oncodermatology working group. vol 10. 2022:A1309-A1309.","DOI":"10.1136\/jitc-2022-SITC2022.1263"},{"key":"2023012010053126000_2023.01.16.23284635v1.35","doi-asserted-by":"publisher","DOI":"10.1177\/001316446002000104"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.01.16.23284635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:25:22Z","timestamp":1768505122000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.01.16.23284635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1101\/2023.01.16.23284635","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1016\/j.jaad.2022.12.048","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,1,18]]},"subtype":"preprint"}}